Configuring Therapeutic Aspects of Immune Checkpoints in Lung Cancer

Immune checkpoints are unique components of the body's defense mechanism that safeguard the body from immune responses that are potent enough to harm healthy body cells. When proteins present on the surface of T cells recognize and bind to the proteins present on other tumor cells, immune check...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2023-01, Vol.15 (2), p.543
Main Authors: Khadela, Avinash, Chavda, Vivek P, Postwala, Humzah, Ephraim, Ramya, Apostolopoulos, Vasso, Shah, Yesha
Format: Article
Language:English
Subjects:
Antigens
Apoptosis
Cell death
Cells
Chemokines
Chemotherapy
Cytokines
Drug delivery
Equilibrium
Immune checkpoint inhibitors
Immune system
Immunoglobulins
Immunology
Immunosuppressive agents
Immunotherapy
Ligands
Lung cancer
Lymphocytes
Lymphocytes T
Medical prognosis
Mutation
Non-small cell lung carcinoma
PD-1 protein
Radiation therapy
Review
Small cell lung carcinoma
Tumor cells
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immune checkpoints are unique components of the body's defense mechanism that safeguard the body from immune responses that are potent enough to harm healthy body cells. When proteins present on the surface of T cells recognize and bind to the proteins present on other tumor cells, immune checkpoints are triggered. These proteins are called immunological checkpoints. The T cells receive an on/off signal when the checkpoints interact with companion proteins. This might avert the host's immune system from eliminating cancer cells. The standard care plan for the treatment of non-small cell lung cancer (NSCLC) has been revolutionized with the use of drugs targeting immune checkpoints, in particular programmed cell death protein 1. These drugs are now extended for their potential to manage SCLC. However, it is acknowledged that these drugs have specific immune related adverse effects. Herein, we discuss the use of immune checkpoint inhibitors in patients with NSCLC and SCLC, their outcomes, and future perspectives.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers15020543